New therapeutic perspectives in CCDC6 deficient lung cancer cells

Francesco Morra, Chiara Luise, Roberta Visconti, Stefania Staibano, Francesco Merolla, Gennaro Ilardi, Gianluca Guggino, Simona Paladino, Daniela Sarnataro, Renato Franco, Roberto Monaco, Federica Zitomarino, Roberto Pacelli, Guglielmo Monaco, Gaetano Rocco, Aniello Cerrato, Spiros Linardopoulos, Mark T. Muller, Angela Celetti

Research output: Contribution to journalArticle

Abstract

Non-small cell lung cancer (NSCLC) is the main cause of cancer-related death worldwide and new therapeutic strategies are urgently needed. In this study, we have characterized a panel of NSC lung cancer cell lines for the expression of coiled-coildomain containing 6 (CCDC6), a tumor suppressor gene involved in apoptosis and DNA damage response. We show that low CCDC6 protein levels are associated with a weak response to DNA damage and a low number of Rad51 positive foci. Moreover, CCDC6 deficient lung cancer cells show defects in DNA repair via homologous recombination. In accordance with its role in the DNA damage response, CCDC6 attenuation confers resistance to cisplatinum, the current treatment of choice for NSCLC, but sensitizes the cells to olaparib, a small molecule inhibitor of the repair enzymes PARP1/2. Remarkably, the combination of the two drugs is more effective than each agent individually, as demonstrated by a combination index

Original languageEnglish
Pages (from-to)2146-2157
Number of pages12
JournalInternational Journal of Cancer
Volume136
Issue number9
DOIs
Publication statusPublished - May 1 2015

Fingerprint

DNA Damage
Lung Neoplasms
Non-Small Cell Lung Carcinoma
Recombinational DNA Repair
Enzyme Inhibitors
Drug Combinations
Tumor Suppressor Genes
Therapeutics
Apoptosis
Cell Line
Neoplasms
Proteins
olaparib

Keywords

  • Candidate biomarker
  • CCDC6
  • DNA damage and homologousdirected repair
  • NSCLC
  • Resistance to platinum salts and PARP-1 inhibitor sensitivity

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Morra, F., Luise, C., Visconti, R., Staibano, S., Merolla, F., Ilardi, G., ... Celetti, A. (2015). New therapeutic perspectives in CCDC6 deficient lung cancer cells. International Journal of Cancer, 136(9), 2146-2157. https://doi.org/10.1002/ijc.29263

New therapeutic perspectives in CCDC6 deficient lung cancer cells. / Morra, Francesco; Luise, Chiara; Visconti, Roberta; Staibano, Stefania; Merolla, Francesco; Ilardi, Gennaro; Guggino, Gianluca; Paladino, Simona; Sarnataro, Daniela; Franco, Renato; Monaco, Roberto; Zitomarino, Federica; Pacelli, Roberto; Monaco, Guglielmo; Rocco, Gaetano; Cerrato, Aniello; Linardopoulos, Spiros; Muller, Mark T.; Celetti, Angela.

In: International Journal of Cancer, Vol. 136, No. 9, 01.05.2015, p. 2146-2157.

Research output: Contribution to journalArticle

Morra, F, Luise, C, Visconti, R, Staibano, S, Merolla, F, Ilardi, G, Guggino, G, Paladino, S, Sarnataro, D, Franco, R, Monaco, R, Zitomarino, F, Pacelli, R, Monaco, G, Rocco, G, Cerrato, A, Linardopoulos, S, Muller, MT & Celetti, A 2015, 'New therapeutic perspectives in CCDC6 deficient lung cancer cells', International Journal of Cancer, vol. 136, no. 9, pp. 2146-2157. https://doi.org/10.1002/ijc.29263
Morra F, Luise C, Visconti R, Staibano S, Merolla F, Ilardi G et al. New therapeutic perspectives in CCDC6 deficient lung cancer cells. International Journal of Cancer. 2015 May 1;136(9):2146-2157. https://doi.org/10.1002/ijc.29263
Morra, Francesco ; Luise, Chiara ; Visconti, Roberta ; Staibano, Stefania ; Merolla, Francesco ; Ilardi, Gennaro ; Guggino, Gianluca ; Paladino, Simona ; Sarnataro, Daniela ; Franco, Renato ; Monaco, Roberto ; Zitomarino, Federica ; Pacelli, Roberto ; Monaco, Guglielmo ; Rocco, Gaetano ; Cerrato, Aniello ; Linardopoulos, Spiros ; Muller, Mark T. ; Celetti, Angela. / New therapeutic perspectives in CCDC6 deficient lung cancer cells. In: International Journal of Cancer. 2015 ; Vol. 136, No. 9. pp. 2146-2157.
@article{940bfc472b9d490ebb3a3df63c018dcd,
title = "New therapeutic perspectives in CCDC6 deficient lung cancer cells",
abstract = "Non-small cell lung cancer (NSCLC) is the main cause of cancer-related death worldwide and new therapeutic strategies are urgently needed. In this study, we have characterized a panel of NSC lung cancer cell lines for the expression of coiled-coildomain containing 6 (CCDC6), a tumor suppressor gene involved in apoptosis and DNA damage response. We show that low CCDC6 protein levels are associated with a weak response to DNA damage and a low number of Rad51 positive foci. Moreover, CCDC6 deficient lung cancer cells show defects in DNA repair via homologous recombination. In accordance with its role in the DNA damage response, CCDC6 attenuation confers resistance to cisplatinum, the current treatment of choice for NSCLC, but sensitizes the cells to olaparib, a small molecule inhibitor of the repair enzymes PARP1/2. Remarkably, the combination of the two drugs is more effective than each agent individually, as demonstrated by a combination index",
keywords = "Candidate biomarker, CCDC6, DNA damage and homologousdirected repair, NSCLC, Resistance to platinum salts and PARP-1 inhibitor sensitivity",
author = "Francesco Morra and Chiara Luise and Roberta Visconti and Stefania Staibano and Francesco Merolla and Gennaro Ilardi and Gianluca Guggino and Simona Paladino and Daniela Sarnataro and Renato Franco and Roberto Monaco and Federica Zitomarino and Roberto Pacelli and Guglielmo Monaco and Gaetano Rocco and Aniello Cerrato and Spiros Linardopoulos and Muller, {Mark T.} and Angela Celetti",
year = "2015",
month = "5",
day = "1",
doi = "10.1002/ijc.29263",
language = "English",
volume = "136",
pages = "2146--2157",
journal = "International Journal of Cancer",
issn = "0020-7136",
publisher = "Wiley-Liss Inc.",
number = "9",

}

TY - JOUR

T1 - New therapeutic perspectives in CCDC6 deficient lung cancer cells

AU - Morra, Francesco

AU - Luise, Chiara

AU - Visconti, Roberta

AU - Staibano, Stefania

AU - Merolla, Francesco

AU - Ilardi, Gennaro

AU - Guggino, Gianluca

AU - Paladino, Simona

AU - Sarnataro, Daniela

AU - Franco, Renato

AU - Monaco, Roberto

AU - Zitomarino, Federica

AU - Pacelli, Roberto

AU - Monaco, Guglielmo

AU - Rocco, Gaetano

AU - Cerrato, Aniello

AU - Linardopoulos, Spiros

AU - Muller, Mark T.

AU - Celetti, Angela

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Non-small cell lung cancer (NSCLC) is the main cause of cancer-related death worldwide and new therapeutic strategies are urgently needed. In this study, we have characterized a panel of NSC lung cancer cell lines for the expression of coiled-coildomain containing 6 (CCDC6), a tumor suppressor gene involved in apoptosis and DNA damage response. We show that low CCDC6 protein levels are associated with a weak response to DNA damage and a low number of Rad51 positive foci. Moreover, CCDC6 deficient lung cancer cells show defects in DNA repair via homologous recombination. In accordance with its role in the DNA damage response, CCDC6 attenuation confers resistance to cisplatinum, the current treatment of choice for NSCLC, but sensitizes the cells to olaparib, a small molecule inhibitor of the repair enzymes PARP1/2. Remarkably, the combination of the two drugs is more effective than each agent individually, as demonstrated by a combination index

AB - Non-small cell lung cancer (NSCLC) is the main cause of cancer-related death worldwide and new therapeutic strategies are urgently needed. In this study, we have characterized a panel of NSC lung cancer cell lines for the expression of coiled-coildomain containing 6 (CCDC6), a tumor suppressor gene involved in apoptosis and DNA damage response. We show that low CCDC6 protein levels are associated with a weak response to DNA damage and a low number of Rad51 positive foci. Moreover, CCDC6 deficient lung cancer cells show defects in DNA repair via homologous recombination. In accordance with its role in the DNA damage response, CCDC6 attenuation confers resistance to cisplatinum, the current treatment of choice for NSCLC, but sensitizes the cells to olaparib, a small molecule inhibitor of the repair enzymes PARP1/2. Remarkably, the combination of the two drugs is more effective than each agent individually, as demonstrated by a combination index

KW - Candidate biomarker

KW - CCDC6

KW - DNA damage and homologousdirected repair

KW - NSCLC

KW - Resistance to platinum salts and PARP-1 inhibitor sensitivity

UR - http://www.scopus.com/inward/record.url?scp=84923212201&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84923212201&partnerID=8YFLogxK

U2 - 10.1002/ijc.29263

DO - 10.1002/ijc.29263

M3 - Article

C2 - 25302833

AN - SCOPUS:84923212201

VL - 136

SP - 2146

EP - 2157

JO - International Journal of Cancer

JF - International Journal of Cancer

SN - 0020-7136

IS - 9

ER -